Cancer types
  • Neuro-oncology
Title of study
A Randomized, Open label,Phase III, Non-inferiority Study to Compare the Efficacy of Re-Irradiation Schedules in Glioma
Version Number
Approval Date 
2.0, 18-03-2020
Short Title
Re-Irradiation Schedules in Glioma (RISinG)
Study site
Principle Investigator
J. Verhoeff
Investigator Maastro
D. Eekers
Sponsor
UMC Utrecht
Trial registry
Objectives 

To determine if re-irradiation in 4 fractions is non-inferior to 10 fractions in the primary endpoint of survival after re-irradiation. Secondary objectives are to establish and compare health related quality of life( HRQoL), neurocognitive function, recurrence patterns, progression free survival, toxicity and anti-edema treatment.

Primary Endpoint 

Overall survival after re-irradiation.

Secondary Endpoints 

The key secondary endpoint is HRQoL. Other secondary endpoints are neurocognitive function(in selected centers), recurrence patterns, progression free survival, toxicityand anti-edema treatment.